Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$2,180 Mln
P/E Ratio
--
P/B Ratio
2.59
Industry P/E
--
Debt to Equity
0.11
ROE
-0.36 %
ROCE
-31.91 %
Div. Yield
0 %
Book Value
11.14
EPS
-2.98
CFO
$-296.69 Mln
EBITDA
$-504.97 Mln
Net Profit
$-503.49 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Kymera Therapeutics (KYMR)
| -14.81 | 15.70 | -15.69 | 2.70 | 1.79 | -- | -- |
|
BSE Sensex
| 2.61 | 3.71 | 5.78 | 8.89 | 11.76 | 20.11 | 11.35 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
|
|---|---|---|---|---|
|
Kymera Therapeutics (KYMR)
| 57.42 | 2.00 | -60.69 | 2.40 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 38.58 | 10,315.11 | 21.27 | 23.13 | |
| 304.46 | 8,705.27 | 22.77 | 66.44 | |
| 27.63 | 10,589.59 | -- | -28.77 | |
| 108.19 | 10,559.67 | 32.44 | 14.16 |
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation... system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis. The company also develops STAT6, a type 2 inflammation in allergic and atopic diseases; and TYK2 to treat autoimmune and inflammatory diseases. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts. Address: 500 North Beacon Street, Watertown, MA, United States, 02472 Read more
Co-Founder & Chairman
Dr. Bruce L. Booth DPHIL, Ph.D.
Co-Founder & Chairman
Dr. Bruce L. Booth DPHIL, Ph.D.
Headquarters
Watertown, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Kymera Therapeutics Inc (KYMR) stood at $ 978 Mln as on 31-Dec-24
The share price of Kymera Therapeutics Inc (KYMR) is $34.27 (NASDAQ) as of 29-Apr-2025 13:35 EDT. Kymera Therapeutics Inc (KYMR) has given a return of 1.79% in the last 3 years.
Kymera Therapeutics Inc (KYMR) has a market capitalisation of $ 2,180 Mln as on 28-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Kymera Therapeutics Inc (KYMR) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Kymera Therapeutics Inc (KYMR) and enter the required number of quantities and click on buy to purchase the shares of Kymera Therapeutics Inc (KYMR).
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis. The company also develops STAT6, a type 2 inflammation in allergic and atopic diseases; and TYK2 to treat autoimmune and inflammatory diseases. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts. Address: 500 North Beacon Street, Watertown, MA, United States, 02472
The CEO & director of Dr. Bruce L. Booth DPHIL, Ph.D.. is Kymera Therapeutics Inc (KYMR), and CFO & Sr. VP is Dr. Bruce L. Booth DPHIL, Ph.D..
There is no promoter pledging in Kymera Therapeutics Inc (KYMR).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,014
|
|
|
1,003
|
|
|
956
|
|
|
867
|
| Kymera Therapeutics Inc. (KYMR) | Ratios |
|---|---|
|
Return on equity(%)
|
-36.38
|
|
Operating margin(%)
|
-475.04
|
|
Net Margin(%)
|
-475.57
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Kymera Therapeutics Inc (KYMR) was $0 Mln.
$0.66
(
